BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-117@pharmaconomics
DTSTAMP:20260707T015521Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:CELG Phase 2 — BMS-986368
DESCRIPTION:Phase 2 trial results for BMS-986368 in Multiple Sclerosis Spasticity are due May 26\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06782490\n\nTrack it: https://pharmaconomics.com/e/117
URL:https://pharmaconomics.com/e/117
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CELG catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR